Role of Nutraceuticals in COVID-19 Mediated Liver Dysfunction

• Main Authors: Mohammed Sikander, Shabnam Malik, Anyssa Rodriguez, Murali M. Yallapu, Acharan S. Narula, Sanjaya K. Satapathy, Vijian Dhevan, Subhash C. Chauhan, Meena Jaggi
• Format: Article
• Language: English
• Published: MDPI AG 2020-12-01
• Series: Molecules
• Subjects: COVID-19; coronavirus; ACE2; hepatic dysfunctions; hepatoprotective agents; nutraceuticals
• Online Access: https://www.mdpi.com/1420-3049/25/24/5905

COVID-19 is known as one of the deadliest pandemics of the century. The rapid spread of this deadly virus at incredible speed has stunned the planet and poses a challenge to global scientific and medical communities. Patients with COVID-19 are at an increased risk of co-morbidities associated with liver dysfunction and injury. Moreover, hepatotoxicity induced by antiviral therapy is gaining importance and is an area of great concern. Currently, alternatives therapies are being sought to mitigate hepatic damage, and there has been growing interest in the research on bioactive phytochemical agents (nutraceuticals) due to their versatility in health benefits reported in various epidemiological studies. Therefore, this review provides information and summarizes the juncture of antiviral, immunomodulatory, and hepatoprotective nutraceuticals that can be useful during the management of COVID-19.